MX2021001361A - Composicion liquida de fibrinogeno humano. - Google Patents

Composicion liquida de fibrinogeno humano.

Info

Publication number
MX2021001361A
MX2021001361A MX2021001361A MX2021001361A MX2021001361A MX 2021001361 A MX2021001361 A MX 2021001361A MX 2021001361 A MX2021001361 A MX 2021001361A MX 2021001361 A MX2021001361 A MX 2021001361A MX 2021001361 A MX2021001361 A MX 2021001361A
Authority
MX
Mexico
Prior art keywords
human fibrinogen
liquid human
fibrinogen composition
composition
liquid
Prior art date
Application number
MX2021001361A
Other languages
English (en)
Inventor
Clémence Debraize
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of MX2021001361A publication Critical patent/MX2021001361A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención propone una composición farmacéutica que comprende entre 10 y 30 g/l de fibrinógeno, entre 10 y 300 mM de arginina y entre 10 y 300 mM de glutamato. Además el pH de la composición está comprendido entre 6 y 8.
MX2021001361A 2016-12-22 2019-06-21 Composicion liquida de fibrinogeno humano. MX2021001361A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1663181A FR3061020B1 (fr) 2016-12-22 2016-12-22 Composition de fibrinogene humain

Publications (1)

Publication Number Publication Date
MX2021001361A true MX2021001361A (es) 2021-04-13

Family

ID=58358663

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007608A MX2019007608A (es) 2016-12-22 2017-12-22 Composicion liquida de fibrinogeno humano.
MX2021001361A MX2021001361A (es) 2016-12-22 2019-06-21 Composicion liquida de fibrinogeno humano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019007608A MX2019007608A (es) 2016-12-22 2017-12-22 Composicion liquida de fibrinogeno humano.

Country Status (16)

Country Link
US (1) US20200093896A1 (es)
EP (1) EP3558381B1 (es)
CN (2) CN117180406A (es)
CY (1) CY1124609T1 (es)
DK (1) DK3558381T3 (es)
ES (1) ES2877848T3 (es)
FR (1) FR3061020B1 (es)
HR (1) HRP20210984T1 (es)
HU (1) HUE055246T2 (es)
LT (1) LT3558381T (es)
MX (2) MX2019007608A (es)
PL (1) PL3558381T3 (es)
PT (1) PT3558381T (es)
RS (1) RS62103B1 (es)
SI (1) SI3558381T1 (es)
WO (1) WO2018115800A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210171587A1 (en) * 2019-12-06 2021-06-10 University Of Wyoming Fibrin particles and methods of forming fibrin particles
CN117794516A (zh) 2021-08-13 2024-03-29 生物测试股份公司 纤维蛋白原组合物和制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE336207C (de) 1916-03-05 1921-04-28 Siemens & Halske Akt Ges Vermittlungsvorrichtung fuer Fernsprechleitungen
AU6104799A (en) 1998-09-24 2000-04-10 Ppl Therapeutics (Scotland) Limited Purification of fibrinogen from fluids by precipitation and hydrophoic chromatography
DE69930653T2 (de) 1998-09-24 2007-01-25 Pharming Intellectual Property Bv Reinigung von fibrinogen aus milch durch den einsatz von kationenaustauschchromatographie
DE10261126A1 (de) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
JP5393447B2 (ja) * 2007-03-22 2014-01-22 一般財団法人化学及血清療法研究所 固体状フィブリノゲン製剤
US8557773B2 (en) * 2008-05-02 2013-10-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Treatment of bleeding with low half-life fibrinogen
CN101371921B (zh) * 2008-10-08 2013-02-13 余美伦 一种速溶冻干纤维蛋白原和凝血酶制剂组合物、制备方法及其用途
CN102286095B (zh) * 2011-07-06 2013-08-21 大田华灿生物科技有限公司 纤维蛋白原的制备方法
KR101127127B1 (ko) * 2011-10-27 2012-03-21 주식회사 녹십자 고농도 피브리노겐 용액의 제조 방법 및 이를 이용한 피브린 실란트 제품의 제조방법
FR3018450B1 (fr) 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines

Also Published As

Publication number Publication date
SI3558381T1 (sl) 2021-11-30
CN117180406A (zh) 2023-12-08
CY1124609T1 (el) 2022-07-22
CN110087689A (zh) 2019-08-02
PT3558381T (pt) 2021-07-01
FR3061020B1 (fr) 2019-05-17
PL3558381T3 (pl) 2021-10-25
ES2877848T3 (es) 2021-11-17
MX2019007608A (es) 2019-08-29
RS62103B1 (sr) 2021-08-31
EP3558381B1 (fr) 2021-04-07
HRP20210984T1 (hr) 2021-09-17
CN110087689B (zh) 2023-09-29
HUE055246T2 (hu) 2021-11-29
LT3558381T (lt) 2021-08-10
FR3061020A1 (fr) 2018-06-29
DK3558381T3 (da) 2021-06-28
WO2018115800A1 (fr) 2018-06-28
US20200093896A1 (en) 2020-03-26
EP3558381A1 (fr) 2019-10-30

Similar Documents

Publication Publication Date Title
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
AU366476S (en) Bottle
MY188696A (en) Cysteine protease
MY187486A (en) Cysteine protease
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
CL2015002897A1 (es) Inhibidores de bace1
MY192532A (en) Liquid pharmaceutical composition
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX2017003121A (es) Formulaciones de anticuerpos.
MX2018013742A (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
MX2018000570A (es) Nuevas isoformas de tripsina y su uso.
PH12017500450A1 (en) Flavivirus virus like particle
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
WO2014197536A3 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
PH12017501979A1 (en) Pharmaceutical compound